Cadila Of India Shows Promising Test Results For “Polypill”
This article was originally published in PharmAsia News
Executive Summary
India's Cadila Pharmaceuticals appears to have a five-drug combination capable of reducing heart disease, according to early clinical trial results. Dubbed the "polypill," it combines blood-pressure, cholesterol-lowering and aspirin drugs into a single pill to reduce heart disease. The trial of just over 2,000 patients showed the combination was capable of reducing heart disease by 60 percent and strokes by half. Cadila sponsored the study of the combination pill, to be provided in a capsule it calls Polycap. (Click here for more